Open-label PET Study with [11C]osimertinib in Patients with EGFRm NSCLC and Brain Metastases

Trial Identifier:	D5160C00043
Sponsor:	AstraZeneca
NCTID::	NCT03463525
Start Date:	October 2018
Primary Completion Date:	March 2020
Study Completion Date:	October 2020
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Swedish Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Sweden	Stockholm, Sweden, SE 11 282

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.